Clinical Trials Directory

Trials / Completed

CompletedNCT03147326

Diagnostic Imaging of Myeloma Bone Lesions

The Diagnostic Value of FDG-PET-CT, NaF-PET-CT and Whole-body MRI Compared to Whole-body Xray in the Detection of Bone Lesions in Multiple Myeloma Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Herlev Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.

Detailed description

Accurate detection of bone lesions in myeloma patients is essential for treatment planning and patient survival. Newly diagnosed multiple myeloma patients can be enrolled in this study. All participants will at time of diagnosis undergo three project scans (FDG-PET-CT, NaF-PET-CT, whole-body MRI) as well as whole-body x-ray as part of clinical routine practice. Experienced specialists in the field of radiology and nuclear medicine interpret the images. Each reader performs the evaluations blinded to other imaging results as well as to the patient's clinical information. The reader assesses whether myeloma indicative bone lesions are present in eight predefined skeletal body regions. Endpoint is purely diagnostic. Statistics: Cochran's Q-test: to compare the proportion of patients with bone disease detected by the four scanning methods. Two-sided ANOVA: to compare the average number of regions detected with bone disease by the four scanning methods. Tukey's comparison test: to compare the difference between each pair of means.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTFDG-PET-CTscanning method
DIAGNOSTIC_TESTNaF-PET-CTscanning method
DIAGNOSTIC_TESTWhole-body MRIscanning method

Timeline

Start date
2012-10-01
Primary completion
2015-09-01
Completion
2017-04-01
First posted
2017-05-10
Last updated
2017-05-10

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03147326. Inclusion in this directory is not an endorsement.